Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6297375 | HELSINN HLTHCARE | 4-phenyl-pyridine derivatives |
Mar, 2023
(a month from now) | |
US10676440 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(12 years from now) | |
US10233154 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(12 years from now) | |
US9951016 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(12 years from now) | |
US10961195 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(12 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8623826 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(7 years from now) | |
US9186357 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(7 years from now) | |
US9943515 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(7 years from now) | |
US8951969 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(7 years from now) | |
US10828297 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Dec, 2030
(7 years from now) | |
US9271975 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Sep, 2031
(8 years from now) |
Market Authorisation Date: 10 October, 2014
Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy
Dosage: CAPSULE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic